Posts Tagged alimta
Developer of mesothelioma treatment honored by Princeton
Posted by Marc in Clinical Trials, Mesothelioma, Mesothelioma Treatment, Research on June 22, 2010
Those fighting malignant pleural mesothelioma have had a new drug at their disposal since it was approved by the FDA in 2004, and it has worked wonders for many – stopping the growth and spread of the cancer, in addition to extending life and relieving patient suffering.
The developer of that drug — Alimta — was honored with a doctoral degree at Princeton’s 263rd commencement exercises earlier this month.
Prof. Edward C. Taylor has been a mainstay at Princeton since 1954, when he first joined the faculty. In 1966, he was appointed Professor of Organic Chemistry – a position he held until 1997, when he was appointed Professor of Organic Chemistry Emeritus and Senior Research Assistant.
With over 450 published scientific papers and the holder of more than 50 patents in the chemistry field, Taylor is one of Princeton’s most tenured and respected researchers.
Alimta® and Gemzar® Effective for Peritoneal Mesothelioma
Posted by Emily in Mesothelioma, Mesothelioma Treatment on July 23, 2008
Re
Peritoneal mesothelioma is much less common than pleural mesothelioma, making up less than 20% of all cases. Moreover, the latency period for peritoneal mesothelioma (sometimes referred to as abdominal mesothelioma) appears to be 20-30 years, which is shorter than the latent period for pleural mesothelioma. The most common treatment strategy for peritoneal mesothelioma involves a multimodality approach with surgical debunking followed by systemic and/or intraperitoneal chemotherapy.
Due to the relative rarity of this disease, controlled trials of various treatment options are not available for peritoneal mesothelioma. Therefore, few studies of chemotherapy for peritoneal mesothelioma, treatment regimens are derived from studies in patients with pulmonary mesothelioma.
This current study involved 20 patients treated between 2002 and 2004. Patients received Alimta and Gemzar every 21 days. In addition, patients also received folic acid, vitamin B12, and dexamethasone. The results from the study are listed below.
- The overall response rate was 15%.
- The disease control rate was 50%.
- The median time to disease progression was 10.4 months.
- The median survival time was 26.8 months.
- Toxicities appeared to be tolerable but with a grade 3-4 neutropenia rate of 60%.
The re
For Full Article, Click Here.
Drug combination effective for elderly mesothelioma patients
Posted by Emily in Mesothelioma, Mesothelioma Treatment, Research on July 10, 2008
In the June 10 edition of the British Journal of Cancer, researchers announced that a combination of two treatments resulted in effective palliative care for elderly mesothelioma patients. Following studies on the drug Alimta, Italian researchers issued a blend of Alimta and the drug Paraplatin to 178 patients with malignant pleural mesothelioma. Overall, the one-year survival rate was 64% and the disease control rate was 76%.
The subjects of the study were also examined according to age. Forty-eight of the patients were over 70 years old; in this group, the disease control rate was 60%, compared to a 67% rate in the younger group. Time to disease progression was 7.2 months versus 7.5 months, and median survival was 10.7 versus 13.9 months for the older age group versus the younger age group, respectively.
Because these data were not significantly different, the treatment regimen was determined to be equally effective among elderly and younger mesothelioma patients. These findings indicate that age should not restrict the use of the Alimta/Paraplatin combination in mesothelioma patients.
For more information, click here.
Alimta shown to slow lung cancers
Posted by Emily in Lung Cancer, Research on May 16, 2008
Eli Lilly & Co. said giving advanced lung cancer patients its Alimta drug after chemotherapy increased patients’ survival without tumor recurrence or progression.
The preliminary study results were released ahead of the company’s presentation later this month at the 44th annual American Society of Clinical Oncology (ASCO) meeting in Chicago.
The trial compared the safety and effectiveness of Alimtra versus a placebo in 663 patients with stage IIIB/IV non-small cell lung cancer, or NSCLC, whose disease had not progressed after four rounds of chemotherapy. Patients given Alimtra lived 4.3 months without their tumors returning or progressing, compared with 2.6 months for patients taking placebo.For more, click here.
Lung cancer and mesothelioma
Posted by Emily in Lung Cancer, Mesothelioma on May 6, 2008
What is the difference between lung cancer and mesothelioma? This is a common question in the minds of many patients, especially after a diagnosis.
Lung cancer and mesothelioma, though similar, are not the same disease. Lung cancer forms in the lung tissue itself, whereas mesothelioma is a cancer that forms in the lung lining.
There are two main types of primary lung cancer: small cell and non-small cell. Small cell lung cancer is named for the tiny size of the tumor cells: most of the cell is occupied by its nucleus. This type of lung cancer spreads very rapidly, so it is typically treated with chemotherapy. Small cell lung cancer is linked very closely with smoking. It is rare for non-smokers to develop this type of cancer.
There are a few kinds of non-small cell lung cancers, but they are all physiologically similar. They respond to treatment differently than small cell lung cancer, and they account for about 85% of all lung cancer cases. Non-small cell lung cancers include:
-Squamous cell carcinoma: linked very closely to smoking and develops in the lung airways
-Adenocarcinoma: develops in the outerairways and the glandular secretory tissue
-Large cell and undifferentiated carcinoma: can develop in any part of the lung
Secondary lung cancer is the term given to cancer that has spread from other organs to the lungs. Because of the high blood supply there, cancers can easily move to the lungs.
Treatments for mesothelioma and lung cancer can sometimes be the same. The drug Alimta, for example, can be used to treat both mesothelioma and non-small cell lung cancers.
To learn more about mesothelioma, click here. For more information on lung cancer, visit the National Cancer Institute website.
-
Follow Us
-
MesoRC on Twitter
-
Most Popular
- About MesoRC and Sokolove Law 8 comment(s)
- Date for Libby Case Set 5 comment(s)
- Looking back on my work with mesothelioma victims 5 comment(s)
- 1976 W.R. Grace Hamster Study: Asbestos Causes Mesothelioma 4 comment(s)
- Asbestos Lawsuit Filed by Estate of Deceased Man 3 comment(s)
- Three-network telethon for cancer airs in September 3 comment(s)
- Mesothelioma: Massage Therapy May Ease Pain in Advanced Cancer 3 comment(s)
- UK to Open Chain Of Cancer Research Centers 3 comment(s)
- Senator Murray's Bill To Ban Asbestos Moves Forward 2 comment(s)
- Permit Granted for Asbestos Removal at Former Green Mountain Race Track Property 2 comment(s)
